title: [Administration of monoclonal antibodies to B-lymphocytes (rituximab) in rheumatoid arthritis in Russia].
abstract: OBJECTIVE
  To assess efficacy and tolerance to anti-B-cell drug rituximab in therapy of rheumatoid arthritis (RA) by the data of RF register of this drug.
  
  
  METHODS
  Rituximab was studied in 42 patients with high RA activity. 37 patients received rituximab according to a conventional scheme: 2 intravenous 1000 mg infusions with a 2-week interval. The rest patients received 2 intravenous 500 mg infusions. The response was evaluated by DAS28 index.
  
  
  RESULTS
  Rituximab administration resulted in almost complete elimination of B-cells from peripheral blood. This produced a significant positive effect manifesting with reduction in the number of inflamed and painful joints. This trend was evident to observation week 8 reaching maximum to week 24. Clinical response correlated with decline of inflammation as shown by ESR and CRP. According to DAS28 index, good and satisfactory results were registered in 8 weeks in 62% patients, in 16 weeks--in 86%, in 24 weeks--in 100%. Rituximab tolerance was good.
  
  
  CONCLUSIONS
  Effective treatment with rituximab for rheumatoid arthritis opened a new perspective in antirheumatic biological therapy and demonstrated an important role of B-cells in the disease development. This drug is recommended for wide use in the treatment of severe rheumatoid arthritis resistant to prior therapy including TNF-alpha blockers.
authors.forename: E L
authors.initials: EL
authors.lastname: Nasonov
authors.forename: G V
authors.initials: GV
authors.lastname: Lukina
authors.forename: Ia A
authors.initials: IaA
authors.lastname: Sigidin
authors.forename: L A
authors.initials: LA
authors.lastname: Bazevich
authors.forename: T I
authors.initials: TI
authors.lastname: Zlobina
authors.forename: R G
authors.initials: RG
authors.lastname: Kamalova
authors.forename: L A
authors.initials: LA
authors.lastname: Kniazeva
authors.forename: V I
authors.initials: VI
authors.lastname: Mazurov
authors.forename: L V
authors.initials: LV
authors.lastname: Men'shikova
authors.forename: A E
authors.initials: AE
authors.lastname: Sizikov
authors.forename: E A
authors.initials: EA
authors.lastname: Smirnova
authors.forename: N A
authors.initials: NA
authors.lastname: Fofonova
authors.forename: T V
authors.initials: TV
authors.lastname: Shabalina
authors.forename: N V
authors.initials: NV
authors.lastname: Shkil'
authors.forename: S S
authors.initials: SS
authors.lastname: Iakushin
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D000069283:Rituximab; D013601:T-Lymphocytes / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D000069283:Rituximab